Imiquimod Patent Expiration
Imiquimod is Used for treating skin conditions caused by certain types of viruses. It was first introduced by Bausch Health Us Llc
Imiquimod Patents
Given below is the list of patents protecting Imiquimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zyclara | US10918635 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | Apr 30, 2030 | Bausch |
| Zyclara | US11202752 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy | Apr 30, 2030 | Bausch |
| Zyclara | US11850245 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | Apr 30, 2030 | Bausch |
| Zyclara | US10238644 | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US11318130 | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US8222270 | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US8236816 | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod | Dec 11, 2029 | Bausch |
| Zyclara | US8299109 | Method of treating actinic keratosis with 3.75% imiquimod cream | Dec 11, 2029 | Bausch |
| Zyclara | US10238645 | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts | Aug 18, 2029 | Bausch |
| Zyclara | US8598196 | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy | Aug 18, 2029 | Bausch |
| Aldara |
US7696159 (Pediatric) | Treatment for basal cell carcinoma |
Oct 01, 2024
(Expired) | Bausch |
| Aldara | US7696159 | Treatment for basal cell carcinoma |
Apr 01, 2024
(Expired) | Bausch |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Imiquimod's patents.
Latest Legal Activities on Imiquimod's Patents
Given below is the list recent legal activities going on the following patents of Imiquimod.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Mar, 2024 | US8299109(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8236816(Litigated) |
| Patent Issue Date Used in PTA Calculation Critical
| 26 Dec, 2023 | US11850245 |
| Recordation of Patent Grant Mailed Critical
| 26 Dec, 2023 | US11850245 |
| Mail Patent eGrant Notification | 26 Dec, 2023 | US11850245 |
| Email Notification Critical
| 26 Dec, 2023 | US11850245 |
| Recordation of Patent eGrant | 26 Dec, 2023 | US11850245 |
| Patent eGrant Notification | 26 Dec, 2023 | US11850245 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Dec, 2023 | US8222270 |
| Email Notification Critical
| 07 Dec, 2023 | US11850245 |
Imiquimod's Family Patents
